The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation

被引：0
|
作者：
Uemura, N [1 ]
Griffin, JD [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2000年 / 96卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3294 / 3295
页数：2
相关论文
共 50 条
  • [1] Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
    Weisberg, E
    Griffin, JD
    BLOOD, 2000, 95 (11) : 3498 - 3505
  • [2] Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571
    Bellone, G
    Ferrero, D
    Carbone, A
    De Quadros, MR
    Gramigni, C
    Prati, A
    Davidson, W
    Mioli, P
    Dughera, L
    Emanuelli, G
    Rodeck, U
    CANCER BIOLOGY & THERAPY, 2004, 3 (04) : 385 - 392
  • [3] Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571
    Corbin, AS
    Buchdunger, E
    Pascal, F
    Druker, BJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) : 32214 - 32219
  • [4] Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
    Thiesing, JT
    Ohno-Jones, S
    Kolibaba, KS
    Druker, BJ
    BLOOD, 2000, 96 (09) : 3195 - 3199
  • [5] Selective induction of apoptosis in K562 cells by a BCR-ABL tyrosine kinase inhibitor, STI571
    Cell Research, 2002, (Z1) : 294 - 294
  • [6] The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
    O'Dwyer, Michael E.
    Druker, Brian J.
    CURRENT CANCER DRUG TARGETS, 2001, 1 (01) : 49 - 57
  • [7] Effects of the tyrosine kinase inhibitor STI571 and ionizing radiation on a human glioblastoma cell line: Potential use as a radiosensitizer.
    Le Coutre, P
    Kreuzer, KA
    Holdhoff, M
    Appelt, C
    Jordan, A
    Scholz, R
    Schwarz, M
    Na, IK
    Lupberger, J
    Schmidt, CA
    BLOOD, 2001, 98 (11) : 179B - 179B
  • [8] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Kawaguchi, Y
    Jinnai, I
    Nagai, K
    Yagasaki, F
    Yakata, Y
    Matsuo, T
    Kuriyama, K
    Tomonaga, M
    LEUKEMIA, 2001, 15 (04) : 590 - 594
  • [9] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Y Kawaguchi
    I Jinnai
    K Nagai
    F Yagasaki
    Y Yakata
    T Matsuo
    K Kuriyama
    M Tomonaga
    Leukemia, 2001, 15 : 590 - 594
  • [10] STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML
    Mauro, MJ
    Druker, BJ
    LEUKEMIA, 2001, 15 (03) : 488 - 488
12345